esmo 2016

Many pivotal studies were presented during the ESMO 2016 Annual Meeting, held from October 7 till 11 in Copenhagen, Denmark. MediPaper summarised the key data of the ESMO 2016, with focus on immunotherapies. Do you know all the key results?

SaveSave

SaveSave

Posts

esmo 2016 breast cancer ribociclib palbociclib abemaciclib data medipaper medicall writer

ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data

Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.

Biomarkers Ipilimumab Treatment MediPaper Medical Communications

Novel Biomarker for Ipilimumab Treatment may aid Future Patient Selection in Several Malignancies

The number of different types of T-helper cells (Th) and cytotoxic T cells (CD8) may predict response to ipilimumab in several malignancies. This was concluded by Dr Juan Pablo Márquez Manríquez who presented the study at the ESMO conference on behalf of the investigators of the Sonora Cancer Research Center (CICS) in Mexico and the United States (U.S.).

ESMO 2016 ipilimumab data medipaper medical communications

ESMO16 Ipilimumab data - Download the PPT

There is no excerpt because this is a protected post.

ESMO 2016 pembrolizumab data medipaper medical communications

ESMO16 Pembrolizumab data - Download the PPT

There is no excerpt because this is a protected post.

ESMO 2016 durvalumab avelumab tremelimumab data medipaper medical communications

ESMO16 Durvalumab, Avelumab, Tremelimumab Data - Download the PPT

There is no excerpt because this is a protected post.

ESMO 2016 atezolizumab data medipaper medical communications

ESMO16 Atezolizumab data - Download the PPT

There is no excerpt because this is a protected post.

ESMO 2016 nivolumab data medipaper medical communications

ESMO16 Nivolumab data - Download the PPT

There is no excerpt because this is a protected post.